Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU4-42P** (RNA, U4 small nuclear 42, pseudogene) is a non-coding RNA gene classified as a pseudogene, which means it resembles a functional gene but has lost its ability to code for a functional product due to mutations or deletions. Pseudogenes are typically not expressed or functional and do not produce biological effects in the cell. There is no evidence that RNU4-42P produces a protein or actively participates in known cellular processes, nor is it known to be involved in disease, serve as a drug target, or function as a biomarker. This distinguishes RNU4-42P from **RNU4-2** (RNA, U4 small nuclear 2), an active non-coding RNA gene of the major spliceosome that has recently been implicated in neurodevelopmental disorders[1][2][3][4]. No studies or drug databases identify RNU4-42P as a functional therapeutic target or as being involved in disease mechanisms.\n\n**Note:**\n- This target is likely an incorrect entry for therapeutic or research purposes. The functional molecule related to pre-mRNA splicing and neurodevelopmental disease is **RNU4-2**, not RNU4-42P.\n- There is no evidence that RNU4-42P has a role as a therapeutic, diagnostic, or pharmacological target in current biomedical literature, nor is it included in disease or drug-target databases[1][2][3][4].\n\nIf you are seeking information on the active, disease-associated U4 small nuclear RNA gene, refer to **RNU4-2**, which encodes the functional U4 snRNA and is fundamental to spliceosome biology and neurodevelopment[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 42, pseudogene (RNU4-42P).